<DOC>
	<DOCNO>NCT01101802</DOCNO>
	<brief_summary>Systemic lupus erythematosus ( SLE ) independent risk factor atherosclerosis . Endothelial dysfunction early marker atherosclerosis measure flow mediate dilation ( FMD ) brachial artery . The purpose study measure FMD mild , stable SLE patient look change FMD immunosuppressant drug mycophenolate mofetil ( MMF ) .</brief_summary>
	<brief_title>Mycophenolate Mofetil Systemic Lupus Erythematosus ( MISSILE )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Female SLE patient Age 1860 year If premenopausal use reliable method contraception Clinically stable disease Taking hydroxychloroquine 15mgs prednisolone daily Smokers Pregnancy breast feed Use immunosuppressant ( hydroxychloroquine stable dose prednisolone 15 mgs daily permit ) Use investigational drug within 1 month prior screen Acute infection 2 week prior Visit 1 History ischaemic heart disease end stage renal disease Current sign symptom severe , progressive uncontrolled hepatic , haematological , gastroenterological , endocrine , pulmonary , cardiac neurological disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>SLE</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Mycophenolate mofetil</keyword>
</DOC>